Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis. by MacManiman, JD et al.
Human Cytomegalovirus-Encoded pUL7 Is a Novel CEACAM1-Like
Molecule Responsible for Promotion of Angiogenesis
Jason D. MacManiman,a* Andrew Meuser,a Sara Botto,a Patricia P. Smith,a Fenyong Liu,b Michael A. Jarvis,a* Jay A. Nelson,a
Patrizia Caposioa
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USAa; Division of Infectious Diseases, School of Public Health, University of
California, Berkeley, California, USAb
* Present address: Jason D. MacManiman, Knight Cancer Center, Oregon Health and Science University, Portland, Oregon, USA; Michael A. Jarvis, School of Biomedicine and
Healthcare Sciences, University of Plymouth, Plymouth, Devon, United Kingdom.
ABSTRACT Persistent human cytomegalovirus (HCMV) infection has been linked to several diseases, including atherosclerosis,
transplant vascular sclerosis (TVS), restenosis, and glioblastoma.We have previously shown that factors secreted fromHCMV-
infected cells induce angiogenesis and that this process is due, at least in part, to increased secretion of interleukin-6 (IL-6). In
order to identify the HCMV gene(s) responsible for angiogenesis promotion, we constructed a large panel of replication-
competent HCMV recombinants. One HCMV recombinant deleted for UL1 to UL10 was unable to induce secretion of factors
necessary for angiogenesis. Fine mapping using additional HCMV recombinants identified UL7 as a viral gene required for pro-
duction of angiogenic factors fromHCMV-infected cells. Transient expression of pUL7 induced phosphorylation of STAT3 and
ERK1/2MAP kinases and production of proangiogenic factors, including IL-6. Addition of recombinant pUL7 to cells was suffi-
cient for angiogenesis and was again associated with increased IL-6 expression. Analysis of the UL7 structure revealed a con-
served domain similar to the immunoglobulin superfamily domain and related to the N-terminal V-like domain of carcinoem-
bryonic antigen-related cell adhesionmolecule 1 (CEACAM1). Our report therefore identifies UL7 as a novel HCMV-encoded
molecule that is both structurally and functionally related to cellular CEACAM1, a proangiogenic factor highly expressed during
vasculogenesis.
IMPORTANCE A hallmark of cytomegalovirus (CMV) infection is its ability to modulate the host cellular machinery, resulting in
the secretion of factors associated with long-term diseases such as vascular disorders and cancer. We previously demonstrated
that HCMV infection alters the types and quantities of bioactive proteins released from cells (designated the HCMV secretome)
that are involved in the promotion of angiogenesis and wound healing. A key proangiogenic and antiapoptotic factor identified
from a proteomic-based approach was IL-6. In the present report, we show for the first time that HCMVUL7 encodes a soluble
molecule that is a structural and functional homologue of the CEACAM1 proangiogenic cellular factor. This report thereby iden-
tifies a critical component of the HCMV secretome that may be responsible, at least in part, for the vascular dysregulation associ-
ated with persistent HCMV infection.
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Human cytomegalovirus (HCMV) is a -herpesvirus that hasbeen epidemiologically linked to several diseases that require
angiogenesis (AG), including atherosclerosis, restenosis following
angioplasty, transplant vascular sclerosis (TVS) associated with
chronic allograft rejection, and glioblastoma (1–4). The best evi-
dence that CMV is directly involved in these pathogenic processes
comes from solid-organ transplantation models (5–7). Specifi-
cally, rat CMV (RCMV) was shown to decrease the mean time to
allograft failure as well as increase the degree of TVS in the allo-
graft vessels in a rat heart transplantation model (5–7). Treatment
of allograft recipient rats with a CMV DNA polymerase inhibitor,
ganciclovir, resulted in prolonged survival of the allograft, indi-
cating that CMV replication was a requirement for acceleration of
disease (8, 9). Microarray analysis of the RCMV-infected heart
allograft transcriptome indicated that a significant number of
RCMV-induced genes, including those encoding angiopoietin,
vascular endothelial growth factor (VEGF), transforming growth
factor beta (TGF-), chemokines, members of the tumor necrosis
factor receptor (TNFR) superfamily, and cytokines such as
interleukin-6 (IL-6), were associated with AG and wound healing
(WH) (10). Together, these results suggest that CMV-mediated
acceleration of TVS occurs through direct or indirect alteration of
AG and WH processes.
HCMV infection of cells in vitro alters the production of bio-
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active proteins released from infected cells into the supernatant
(HCMV secretome) that, when applied to endothelial cell cul-
tures, induce an angiogenic phenotype (11). Many of these factors
have important roles in vascular disease, and we have hypothe-
sized that a major role of CMV infection in the acceleration of TVS
occurs through the increased production of AG/WH factors
within the allograft. Mass spectrometry analysis of HCMV-
infected and mock-infected secretomes identified more than
1,200 soluble proteins, more than 1,000 of which were specific to
or highly enriched in the HCMV secretome. Pathway analysis in-
dicates that a large number of angiogenic molecules, i.e., proteins
involved in TGF- and other factor signaling pathways, cytokines,
and chemokines, as well as factors involved in extracellular matrix
remodeling, are present in the HCMV secretome. Importantly, we
demonstrated that the HCMV secretome contains high levels of
IL-6 that promote AG and long-term survival of endothelial cells
(EC). In EC, IL-6 prevented apoptosis by blocking caspase 3 and 7
activation through the induction of survivin (12). Although the
identity of the HCMV gene(s) responsible for AG is unknown, this
function was shown to be due to an HCMV late gene, since a drug
that blocks the viral polymerase function also inhibits the ability of
viral supernatants to induce neovessel formation.
In the current study, mutational analysis of the HCMV ge-
nome identified UL7 as the viral gene responsible for induction of
AG factors during HCMV infection. UL7 is a late gene encoding a
transmembrane protein that is cleaved to produce a small soluble
protein secreted from the cell (13). We show that UL7 is sufficient
to induce the AG phenotype and is structurally and functionally
related to carcinoembryonic antigen-related cell adhesion mole-
cule 1 (CEACAM1), a cellular protein that also induces AG.
RESULTS
HCMV-induced angiogenesis is mediated by the UL7 late gene.
In order to identify the HCMV gene involved in AG, we generated
a library of 6 recombinant viruses with large-scale deletions of
nonessential open reading frames (ORFs) that include HCMV
TR-bacterial artificial chromosome (BAC) UL1 to UL10
(UL1–10), UL11–20, UL22–25, UL118 –121, US7–12,
and US15–22. Analysis of secretomes from these HCMV dele-
tion mutants in a Matrigel angiogenesis assay indicated that only
deletion of UL1–10 significantly decreased tubulogenesis in hu-
man aortic endothelial cells (HAEC) (70%) (Fig. 1A). The micros-
copy pictures (Fig. 1B) show some differences between the mock
secretome and the UL1–10 mutant; however, the structures pres-
ent in the TRUL1–10 secretome are mainly branching cells
rather than lumens delimited by intact capillary-like tubule struc-
tures. As secretomes do not contain infectious virus, this finding
suggests a direct or indirect role of HCMV protein(s) from the
UL1–10 region in release of soluble proangiogenic factors.
In order to determine which of the HCMV genes encoded in
the TR UL1–10 mutant were responsible for HCMV-induced
AG, a library of HCMV Towne mutants with transposon muta-
tions in UL3, UL4, UL5, UL6, UL7, UL8, UL9, or UL10 was used to
generate secretomes in fibroblasts (14). The UL2 mutant was not
included in these studies since this virus exhibits a growth defect
(14). The role of UL1 was also not examined since the parental
HCMV Towne strain contains a spontaneous deletion in this gene
that does not affect the ability of the virus to induce a secretome
that stimulates AG (15). Analysis of HCMV mutant secretomes
for induction of AG indicated that mutation of UL7 resulted in a
50% reduction of tubulogenesis (Fig. 1C). As further confirma-
tion that UL7 was important for HCMV-induced AG, an HCMV
UL7 mutant was generated in the clinical strain TR (TR
stopUL7HA) by insertion of two stop codons as well as an influ-
enza virus hemagglutinin (HA) epitope tag in frame at the 3= end
of the UL7 ORF. A correlate HCMV TR revertant virus (TR wild-
type UL7HA [wtUL7HA]) was also constructed by replacing the
stopUL7-HA cassette with a functional UL7-HA insertion (see
Fig. S1 in the supplemental material). The replication kinetics of
TR wtUL7HA and TR stopUL7HA were similar to those seen with
the TR wt (see Fig. S2). Expression of UL7 in TR wtUL7HA- or TR
stopUL7HA-infected cells was determined by immunofluores-
cence using antibodies to the HA epitope, with results indicating
that only the revertant virus expressed UL7 (see Fig. S3). Subse-
quently, analysis of secretomes obtained from TR stopUL7HA-
and TR wtUL7HA-infected HAEC indicated that only the rever-
tant virus and not the UL7 mutant induced AG (Fig. 1D and E).
These results demonstrate that UL7 is the gene within the UL1–10
region required for HCMV-induced AG.
UL7 is a novel CEACAM-like protein and is sufficient to in-
duce angiogenesis. UL7 is a member of the HCMV RL11 gene
family (15, 16). Previous studies indicated that UL7 is expressed as
an early-late gene and encodes a 222-amino-acid type I glycopro-
tein, which is proteolytically cleaved to release a heavily glycosy-
lated ectodomain (13). The late gene expression of UL7 was con-
firmed by Northern blotting (see Fig. S4 in the supplemental
material) and is consistent with the previous observation that
HCMV-induced AG is due to expression of a viral late gene (11).
Although pUL7 was previously reported to have homology to the
CD229 lymphocyte-activating molecule receptor (13), a query of
the HCMV TR UL7 protein against NCBI GenBank conserved
domains revealed a similarity to the first Ig-like domain of the
carcinoembryonic antigen (CEA)-related cell adhesion molecule
(CEACAM) protein subfamily (cd, 05741; E value, 3.90e-04). A
BLASTp alignment performed with the four members of the
CEACAM family (CEACAM1, CEACAM3, CEACAM5, and
CEACAM6) displayed 39% similarity and 29% amino acid iden-
tity between the UL7 Ig-like domain and the N-terminal V-like
domain of CEACAM1 (Fig. 2). Interestingly, the CEACAM1 mol-
ecule is highly expressed during vasculogenesis (17), and soluble
recombinant CEACAM1 added to endothelial cell cultures has
been shown to stimulate significant tubule formation (18).
To confirm that UL7 is cleaved from the cell surface, HEK293
cells were transfected with a plasmid expressing pUL7 tagged at
the C terminus with a HA epitope. After 48 h, immunoblot anal-
yses of cell lysates by the use of an antibody specific for the HA
epitope and of supernatants by the use of a specific polyclonal UL7
antibody were performed. Two prominent bands of 75 and
12 kDa, corresponding to the UL7 precursor and the cytoplasmic
tail, were detected in the pUL7HA-expressing cells. PNGaseF
treatment led to a reduction of the UL7 precursor to the predicted
molecular mass of 25 kDa (see the left panel of Fig. S5 in the
supplemental material). In the supernatant of the transfected cells,
only the 75-kDa ectodomain was present, demonstrating that
pUL7 is partially cleaved in HEK293 cells (see Fig. S5, right panel).
To allow us to express detectable levels of pUL7 in HAEC, we
constructed an adenoviral vector expressing pUL7HA (designated
AdUL7). Western blotting of cell lysate from HAEC transduced
with AdUL7 showed the 12-kDa protein, corresponding to cyto-
plasmic tail regions of UL7, and a faint band around 75 kDa
MacManiman et al.
2 ® mbio.asm.org November/December 2014 Volume 5 Issue 6 e02035-14
*** *** 
*** *** 
Mock scr TR scr TR UL1-10 scr 
A 
B 
Lumens Branch points
0
25
50
75
100
125
150
175
200
Mock s cr
TR  s cr
TRΔUL1-10 s cr
TRΔUL11-20 s cr
TRΔUL22-25 s cr
TRΔUL118-121 s cr
TRΔUS 7-12 s cr
TRΔUS 15-22 s cr
N
um
er
ic
al
 v
al
ue
C 
** 
** 
Lumens Branch points
0
25
50
75
100
125
SF-EBM2
S-EGM2
Mock scr
TRwtUL7HA scr
TR stopUL7HA scr
N
u
m
er
ic
al
 v
al
u
e
Mock scr TR wtUL7HA scr TR stopUL7HA scr 
D 
E 
*** *** 
*** *** 
Lumens Branch points
0
25
50
75
100
125
150
175
200
225
Mock s cr
Towne s cr
TowneΔ
Δ
UL3 s cr
TowneΔUL4 s cr
TowneΔUL5 s cr
TowneΔUL6 s cr
TowneΔUL7 s cr
TowneΔUL8 s cr
TowneΔUL9 s cr
TowneΔUL10 s cr
N
um
er
ic
al
 v
al
u
e
FIG 1 Deletion of UL7 within the UL1–10 region impaired tubulogenesis. (A) Quantitative measures of angiogenesis consisting of the numbers of lumens and
branch points observed in the presence of secretomes generated from mock infections (Mock scr), TR secretome (TR scr), TRUL1–10 secretome (TRUL1–10
scr), TRUL11–20 secretome (TR UL11–20 scr), TRUL22–25 secretome (TR UL22–25 scr), TRUL118 –121 secretome (TR UL118 –121 scr),
TRUS7–12 secretome (TRUS7–12 scr), and TRUL15-12 secretome (TRUS5-12 scr). Three independent experiments were performed. Data are expressed
as means SEM of the results of three independent biological replicates for each viral construct assayed in triplicate. Statistical significance is represented with
three asterisks (***; P 0.001). (B) Representative examples of mock secretome (Mock scr), HCMV TR secretome (TR scr), and HCMV TRUL1–10 secretome
(TRUL1–10 scr) are shown as a low-power image (magnification,10). (C) HFFF cells were infected with wild-type Towne (wt Towne), TowneUL3, Towne
UL4, Towne UL5, Towne UL6, Towne UL7, Towne UL8, Towne UL9, and Towne UL10 or were mock infected. Secretomes were collected at 96 hpi
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(Fig. 3A), suggesting that the ectodomain of pUL7 in EC is mainly
released from the cells. Secretomes were harvested from cells
transduced with AdUL7 or adenovirus construct expressing green
fluorescent protein (AdGFP) and examined for the ability to in-
duce AG. As shown in Fig. 3B and C, only the secretome from
HAEC transduced with AdUL7 was capable of inducing a consis-
tent network of interconnecting tubules. To determine whether
the ectodomain of pUL7 was sufficient to induce AG, we assessed
the angiogenic properties of a recombinant protein containing
only the extracellular domain of UL7 fused to the Fc region of the
mouse IgG heavy chain. As shown in Fig. 4, stimulation of HAEC
with pUL7Fc, but not with Fc alone, resulted in a dose-dependent
increase of tubule formation that was inhibited by preincubation
of pUL7Fc with an anti-UL7 polyclonal antibody. Human recom-
binant CEACAM1Fc was used as a positive control. To verify the
hypothesis that UL7 is binding a cellular receptor on the cell sur-
face, we performed a flow cytometry-based binding assay with
purified pUL7Fc or Fc alone, demonstrating the specific interac-
tion of UL7 with CD31-positive HAEC (see Fig. S6). These data
indicate that the pUL7 ectodomain is sufficient to induce the pro-
duction of angiogenic factors in the cellular secretome.
HCMVUL7 induces the production of IL-6 that is associated
with increased STAT3 and extracellular signal-regulated kinase
1 (ERK1) and ERK2 (ERK1/2) phosphorylation. We previously
reported that HCMV-induced AG is mediated by viral induction
of IL-6 in the secretome (12). To determine whether pUL7 in-
duced the production of IL-6, HAEC transduced with AdUL7 or
AdGFP were analyzed for IL-6 production. As shown in Fig. 5A,
transduction of cells with AdUL7 resulted in an ~12-fold increase
in production of IL-6 in comparison to the AdGFP results. These
observations are also consistent with the 10-fold-lower level of
IL-6 release seen following infection of cells with the UL7 mutant
(TR stopUL7HA) compared to the revertant virus TRwtUL7HA at
96 h postinfection (hpi) (Fig. 5B). To determine whether extracel-
lular addition of UL7 induced production of IL-6, pUL7Fc was
added to cells followed by quantification of the cytokine in super-
natants. As shown in Fig. 5C, addition of pUL7Fc to HAEC was
sufficient to induce secretion of IL-6 within the first 24 h.
Consistent with the release of IL-6 in the supernatant of
AdUL7-transduced HAEC, we observed elevated levels of
phospho-STAT3 and phospho-ERK1/2 at 48 hpi, compared to the
control AdGFP-transduced cell results (Fig. 6A). To investigate
the phosphorylation status of STAT3 and ERK1/2 during HCMV
infection, we infected HAEC with TR wtUL7HA and TR
stopUL7HA. Western blot analysis of cells infected with TR
wtUL7HA for 96 h showed a 35-fold increase in phospho-STAT3
and a 10-fold increase in phospho-ERK1/2 levels compared to the
mock-infected cell results. The level of phospho-STAT3 in HAEC
infected with TRstopUL7HA was 12-fold higher than that seen
with the mock infection, while the level of phospho-ERK1/2 was
comparable to that seen with the mock infection (Fig. 6B). In
order to determine whether soluble pUL7 binding to the cells
induced IL-6 production, pUL7Fc was added to cultures of HAEC
at increasing concentrations. As shown in Fig. 6D, addition of
pUL7Fc resulted in IL-6 production, with optimal effects ob-
served at 300 ng/ml. Moreover, pUL7Fc induced STAT3 and
ERK1/2 phosphorylation (Fig. 6C). Treatment with neutralizing
antibodies against pUL7 or IL-6 resulted in an 80% decrease in
IL-6 secretion and a 40% reduction in STAT3 phosphorylation
(Fig. 6D).
Finally, treatment of pUL7Fc-stimulated HAEC with either an
ERK1/2 (PD98059) or a STAT3 (STX-0119) inhibitor resulted in
decreased tubule formation and IL-6 secretion (Fig. 7).
Together, these observations indicate that binding of secreted
pUL7 to an unknown cellular receptor on HAEC induces IL-6
through the activation of STATs and of ERK1/2-mitogen-
activated protein kinase (MAPK) pathways.
DISCUSSION
In the present study, we demonstrated that the presence of HCMV
pUL7 is sufficient to induce endothelial cell angiogenesis. Inter-
estingly, pUL7 is a secreted viral protein and contains an Ig-like
domain with structural and functional homology to CEACAM1, a
molecule highly expressed during vasculogenesis. We found that
UL7 expression stimulates an inflammatory response in EC, in-
ducing the secretion of IL-6 and the activation of STATs and of
MAPK pathways. Importantly, these findings identify a mecha-
nism by which HCMV can influence and manipulate the vascular
environment despite limited infection of the vessel wall.
The CMV genome encodes 12 multigene families (16, 19), in-
cluding the RL11 family, which contains the RL11–13, UL1, and
UL4 –11 genes (20). All members of the RL11 family are located
adjacent to each other near the left terminus of the genome and are
dispensable for virus growth in vitro (14). Among the RL11D
CEACAM1      1  SGGAQLTTESMPFN-VAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQA
TR UL7       36 ------ILESVIYVSGPQGGNVTL-ISNFTS-NISVRWFRWDGNDS-HLICFYKRGEGLS
                        **: :    :* :* * : *: .  :.  *:: :  *. : *  *  *   :
CEACAM1      TPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVY------ 111
TR UL7       TPYV---GLSLSCAANQITIFNLTLNDSGRYGAEGFTRS----GENETFLWYNLTVKP 102
             **     * .      .: * *:* **:* *  : :. .      .  *  *
FIG 2 UL7 is a homologue of secreted CEACAM1. An alignment of the sequences of the V-set Ig domain of CEACAM1 and UL7 is shown. Asterisks, colons,
and dots indicate identical amino acid residues, conserved amino acid residues, and semiconserved amino acid residues, respectively.
Figure Legend Continued
and tested in a Matrigel assay using HAEC. Three independent experiments were performed. Data are expressed as means  SEM of the results of three
independent biological replicates for each viral construct assayed in triplicate. Statistical significance is represented with two asterisks (**; P 0.01). (D) HAEC
were infected with TR wtUL7HA or TR stopUL7HA and secretomes collected at 96 hpi. Statistical significance is represented with three asterisks (***; P 0.001).
(E) Representative examples of mock secretome (Mock scr), TR wtUL7HA secretome (TR wtUL7HA scr), and TR stopUL7HA secretome (TR stopUL7HA scr)
are shown as a high-power image (magnification,20).
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FIG 4 Recombinant UL7 promotes HAEC tube formation. Increasing concentrations (50, 150, and 300 ng/ml) of pUL7Fc were directly added to serum-free
basal media in the presence or absence of neutralizing antibodies against UL7 or the isotype control (iso ctl). Controls included HAEC stimulated with 300 ng/ml
of Fc and 300 ng/ml of CEACAM1Fc. (A) Quantitative measures of angiogenesis consisted of the numbers of lumens and branch points. Three independent
experiments were performed. Data are expressed as means SEM of the results of three independent biological replicates for each condition assayed in triplicate.
Statistical significance is represented with three asterisks (***; P 0.001) or with two asterisks (**; P 0.01). (B) Representative examples of Fc, pUL7Fc, and
pUL7Fc plus UL7 (pUL7FcUL7) are shown as a high-power image (magnification,20).
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genes, UL7 exhibits high sequence conservation across different
CMV genotypes (97% to 100% intra- and 83% to 93% intergeno-
type conservation), suggesting a critical role of UL7 for viral fit-
ness (15). Consistent with the literature data, we found that pUL7
is shed from HAEC cells and that the transcript is expressed in the
late phase of the viral replication cycle. Upon further sequence
inspection of pUL7, however, we identified homology with the
first Ig-like domain of the carcinoembryonic antigen (CEA)-
related cell adhesion molecule (CEACAM) protein subfamily. In-
terestingly, another HCMV RL11 protein, UL1, which is virion
associated and required for efficient replication in epithelial cells,
had previously been reported to share sequence homology with
CEACAM1 (21). Because RL11 members are more likely the de-
scendants of a common cellular ancestor that was incorporated
into the HCMV genome, duplicated, and subsequently subjected
to functional divergence during coevolution with the host, pUL7
may have evolved to mimic the angiogenic properties of soluble
CEACAM1 whereas pUL1 has retained the receptor function con-
tributing to HCMV access to host cells by interacting with mem-
bers of the CEA family.
CEACAM1 is a transmembrane cell adhesion molecule that is
abundantly expressed in epithelia, vessel endothelia, and hemato-
poietic cells (22). In primary EC culture, recombinant human
CEACAM1 enhances the sprouting and migration of EC, acting
synergistically with VEGF (18). EC produces both secreted and
membrane-bound forms of CEACAM1. The soluble CEACAM1
form may stimulate proliferation and chemotaxis of EC, whereas
the membrane-bound form may be involved in morphogenic
events such as formation of capillary tubes. Moreover, lack of
endothelial CEACAM1 expression in Ceacam1/ mice leads to
defective vascular remodeling in vivo, whereas endothelial overex-
pression of CEACAM1 in CEACAM1endomice induces extensive
vascular growth (23). Membrane-bound CEACAM1 can have a
long (L) or a short (s) cytoplasmic domain (24). Both isoforms are
coexpressed in most CEACAM1-expressing tissues, and the ratio
between the two isoforms determines the signaling outcome (25,
26). The structural and functional homology of UL7 with
CEACAM1 and the inter-strain-specific conservation level reflect
the existence of a selective pressure against mutations in the pro-
tein sequence, supporting a relevant role of this viral product. The
short cytoplasmic tail of pUL7 resembles the “s” isoform of
CEACAM1, suggesting that pUL7 does not function as a signal
receptor but more likely evolved to mimic the angiogenic proper-
ties of soluble CEACAM1. However, our studies presented here do
not rule out a possible function for the membrane-bound form, in
addition to the AG functions of the soluble form.
We have previously shown that one of the key cytokines pres-
ent in the HCMV secretome is IL-6, which promotes AG and
blocks apoptosis through increased levels of survivin (12). The
inflammatory effects of IL-6 have been implicated as a factor in the
failure of organ and tissue grafts, and elevated levels of the cyto-
kine have been reported to accompany HCMV replication in
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for 24 h. ELISA was used to quantify the amount of IL-6 secreted from HAEC. Cell lysates were analyzed by Western blotting with specific antibodies for
phospho-STAT3, total STAT3, and actin.
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transplanted lungs and bone marrow during episodes of inflam-
mation or rejection (27–29). Interestingly, we found that binding
of pUL7 stimulates an inflammatory response in vascular endo-
thelial cells that leads to IL-6 secretion. Our data are therefore in
contrast with the observations by Engel et al., who reported that
activated monocyte-derived immature dendritic cells (DCs) and
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FIG 7 Pharmacological inhibition of STAT3 or ERK1/2 phosphorylation impairs pUL7-induced AG and IL-6 secretion. HAEC were incubated in the presence
of 300 ng/ml of Fc, pUL7Fc, pUL7Fc with 50 M of ERK1/2 inhibitor PD98059, and pUL7Fc with 50 M of STAT-3 inhibitor STX-0119. (A) Quantitative
measures of angiogenesis consisted of the numbers of lumens and branch points. Three independent experiments were performed. Data are expressed as means
 SEM of the results of three independent biological replicates for each conditions assayed in triplicate. Statistical significance is represented with two asterisks
(**; P 0.01). (B) Representative examples of Fc, pUL7Fc, pUL7FcPD9859, and pUL7FcSTX-0119 are shown as a high-power image (magnification,20).
(C) ELISA quantification of IL-6 levels and immunoblotting on cell lysates with specific antibodies for phospho-STAT3, total STAT3, and actin.
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monocytic cell lines transiently expressing pUL7 secreted less
IL-8, IL-6, and tumor necrosis factor (TNF) than the control cells
(13). It is possible that the binding of pUL7 with its cellular recep-
tor(s) triggers a pro- or anti-inflammatory response depending on
the role played by different cell types in HCMV spread and persis-
tence in the host. For example, CEACAM1-L, upon activation, can
discriminate between binding of cytoplasmic protein tyrosine
phosphate SHP-1/SHP-2 and binding of Src family tyrosine ki-
nases in a manner that is regulated by and dependent on
CEACAM1-L supramolecular organization. The discriminatory
binding of SHP-1/SHP-2 and of Src is the basis for the different
effects of signal regulation by CEACAM1, which have found to be
both inhibitory and stimulatory (30).
Notably, the concentration of IL-6 was increased after AdUL7
transduction or addition of recombinant pUL7Fc protein (Fig. 5A
and C). IL-6 is a potent, pleiotropic, inflammatory cytokine that
mediates multiple physiological functions, including develop-
mental differentiation of lymphocytes, cell proliferation, cell sur-
vival, and inhibition of apoptotic signals (31–34). IL-6 mRNA has
also been detected in human atherosclerotic lesions, indicating
that this cytokine is expressed at the site of injury (35). Engage-
ment of IL-6 with the IL-6 receptor activates three main signaling
pathways, the JAK/STAT, ERK1/2-MAPK, and phosphoinositol
3-kinase (PI3K)/Akt pathways (36, 37). Activation of the JAK-
STAT pathway was reported to have short-term cardioprotective
effects as well as long-term inflammation-promoting effects (38).
ERK1/2-MAPK activation has been implicated in hypertrophy
and cell survival (39). IL-6 and the JAK/STAT and MAPK path-
ways are also linked to malignant glioblastoma through the ex-
pression of the US28 HCMV chemokine receptor (40). US28 ac-
tivity might be responsible for the residual activation of STAT3
and ERK1/2 in TR stopUL7HA-infected cells compared to the
mock-infected cell results (Fig. 6B).
In conclusion, we show for the first time that HCMV encodes a
homologue structurally and functionally similar to CEACAM1.
Ongoing and future work will be focused on the identification of
the UL7 cellular receptor(s) as well as on the function of this viral
gene in HCMV pathogenesis. Thus, alteration of UL7 binding or
cell signaling may offer a novel strategy for the treatment of the
angiogenic processes involved in HCMV-associated vascular dis-
eases.
MATERIALS AND METHODS
Cells and virus preparation. Human aortic endothelial cells (HAEC)
(Lonza) were cultured in endothelial growth medium (EGM-2; Lonza), as
previously described (12). Human fetal foreskin fibroblasts (HFFF) (pur-
chased from Sigma) were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) (Cellgro; Corning) supplemented with 10% fetal bovine
serum (FBS) (HyClone; Thermo Scientific), 4.5 g/liter glucose,
L-glutamine and sodium pyruvate, and antibiotics (penicillin [10 units/
ml]-streptomycin [10 g/ml]). The human embryonic kidney 293 cell
line (HEK293) and HEK293/Cre4 cell line (Microbix Biosystems Inc.)
were cultured in minimum essential medium (MEM) (Cellgro; Corning)
supplemented with 10% FBS, penicillin, streptomycin, and L-glutamine.
PD98058 was purchased from Cell Signaling Technology and STAT3 in-
hibitor XI (STX-0119) from Calbiochem. HCMV strain TR was derived
originally from a patient with AIDS-related HCMV retinitis (41) and was
cloned into a bacterial artificial chromosome (BAC) (NCBI accession no.
AC146906) (42). Infectious virus was produced and titers were deter-
mined by plaque assays on HFFF as previously described (12).
Plasmids. Full-length UL7 containing a hemagglutinin (HA) epitope
tag in frame at the 3= terminus of the ORF was obtained by PCR using
DNA extracted from HCMV TR virions as the template and the primers
listed in Table S1 in the supplemental material. UL7HA containing two
stop codons, one at codon 6 and the second at codon 221, was generated
by PCR using pGEM-UL7HA as the template and the primers listed in
Table S1. pCDNA3-UL7HA was generated by PCR amplification of
UL7HA from pGEM-T Easy using the primers listed in Table S1. For
construction of UL7HA recombinant adenovirus, the respective ORF was
amplified from TR DNA with the primers listed in Table S1, digested with
EcoRI and BamHI, and then cloned into the pAdTet7 adenoviral vector.
For construction of recombinant pUL7Fc, a PCR product was amplified
from TR DNA using the primers listed in Table S1, digested with AscI and
NotI, and then cloned into pCMV6-AC-Fc-S plasmid (Origene).
Construction of recombinant HCMV TR mutants. Recombinant
TRUL1–10 was constructed by E/T recombination using pBSKSII plus
NaeI/SspI/MCS vector as the template to generate the PCR product and
the primers listed in Table S1 in the supplemental material as previously
described (43). Restriction enzyme digestion combined with DNA se-
quence analysis confirmed deletion of UL1–10 from the HCMV TR-BAC
genome.
TR stopUL7HA and TR wtUL7HA BAC were constructed using the
galactokinase (Galk) recombineering method (see Fig. S1 in the supple-
mental material) (44). In the first step, the galactokinase-kanamycin
(Galk/Kan) ORF was amplified from pYD-C255, a GalK-Kan dual-
expression plasmid (a gift from D. Yu, Washington University in St.
Louis), using primers listed in Table S1. One of the single Gal-positive
(Gal) TRUL7 BAC colonies was further characterized for UL7 replace-
ment by PCR and used to initiate the counterselection step. To replace the
Galk/Kan cassette in the second step, UL7 was amplified from pGEM-
stopUL7HA plasmid using oligonucleotides listed in Table S1. Two inde-
pendent TR stopUL7HA BAC clones were thus selected and produced to
ensure that their phenotype did not result from an off-target mutation. To
generate the revertant HCMV TR wtUL7HA-BAC, the insertion and sub-
stitution of the Galk/Kan cassette were repeated with a PCR product gen-
erated from the pGEM-UL7HA plasmid. Oligonucleotide primers used
for the revertant TR wtUL7HA BAC are listed in Table S1. Recombinant
viruses were screened by BAC digestion, PCR, and sequencing. Recombi-
nant viruses were produced by electroporation of the corresponding
BACs into HFFF. Virus stocks were propagated and stored and titers were
determined as described above.
Adenovirus production. Recombinant adenoviruses were produced
by pAdTet7 UL7HA cotransfection of 293-Cre cells with Ad DNA (Ad5-
5) (45). Recombinant adenoviruses were expanded on 293-Cre cells, and
the titers of the bulk stocks were determined on 293 cells by limiting
dilution. Gene expression was driven by coinfection with Ad-Trans ex-
pressing the Tet-off transactivator as previously described (46). The re-
combinant adenoviral vector expressing green fluorescent protein (GFP)
was a gift from D. Streblow at Oregon Health & Science University
(OHSU) (47).
Preparation ofHCMVand adenoviral secretomes.HCMV TR secre-
tomes were generated by infecting HAEC at a multiplicity of infection
(MOI) of 3 PFU/cell for 96 h, as previously described (12). HCMV Towne
secretomes were generated in fibroblasts infected at an MOI of 0.5 and
harvested 96 hpi. For the adenovirus secretome, HAEC were starved for
12 h in serum-free endothelial basal medium-2 (SF-EBM2) and then
coinfected with the appropriate adenovirus and transactivator (MOI of
250 PFU/cell). The supernatant from infections was harvested and clari-
fied at 48 hpi.
Angiogenesis assay. The ability of secretomes to induce angiogenic
activity was measured using a modified version of the standard Matrigel in
vitro tubule formation assay, as previously described (12). For experi-
ments involving neutralization, the secretome containing anti-UL7 anti-
body or an anti-rabbit isotype control was incubated for 1 h at 37°C prior
to stimulation of HAEC.
Fc fusionUL7 and antiserumproduction. To express UL7 in a glyco-
sylated form comparable to that of the native protein, stable clones were
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made by transfection of HEK293 with pCMV6-UL7Fc and selection with
neomycin (G418; Gibco-BRL). Stable clones with G418 resistance were
obtained by trypsinization of colonies, followed by plating at limiting
dilutions onto a 96-well plate. Ten single clones were then expanded and
analyzed for UL7 secretion by the use of mouse Fc and an IgG enzyme-
linked immunosorbent assay (ELISA) kit (MednaBio). The clone produc-
ing the largest amounts of fusion protein was cultured in EX-Cell 293
serum-free medium (Sigma-Aldrich). The supernatant containing the fu-
sion protein was purified using a HiTrap protein A HP column (GE
Healthcare) according to the manufacturer’s specifications.
To generate an anti-UL7 serum, the recombinant protein was used for
rabbit immunization. The serum obtained by bleeding at 10 days after the
fourth immunization was purified on an HiTrap protein A HP column
(GE Healthcare) according to the manufacturer’s specifications. An iso-
type control was generated by purifying rabbit serum prior immuniza-
tion. Fc and CEACAM1 recombinant proteins were purchased at R&D
Systems.
Immunoblotting. Extracts were run on an 8% to 12% SDS-PAGE gel,
transferred to Immobilon-P transfer membranes (Milipore Corp.), and
visualized with antibodies specific for phospho-STAT3 (Tyr705 and 3E2;
Cell Signaling), STAT3 (79D7; Cell Signaling), phospho-ERK1/2 (Thr202
and Tyr204; Cell Signaling Technology), ERK1 (C16; Santa Cruz), mouse
monoclonal UL99 (pp28) and HA (HA-7; Sigma), rabbit UL7, and actin
(C4; Millipore).
IL-6 immunoassay. A double-antibody sandwich enzyme-linked im-
munosorbent assay (ELISA) for the quantitative determination of human
IL-6 levels in tissue culture media was performed on the stored superna-
tants according to the manufacturer’s recommended procedure (R&D
Systems).
Sequence analysis. Conserved domains in the UL7 sequence were
identified using the NCBI Conserved Domain program (http://
www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). Protein sequence
alignment was performed using the NCBI Basic Local Alignment Search
Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis. Data are expressed as means standard errors of
the means (SEM). Statistical significance of differences was determined by
Student’s t test and considered significant at P values of 0.05.
SUPPLEMENTAL MATERIAL
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